The role of targeted therapy in thymic carcinoma

Mridula Krishnan, Apar K. Ganti

Research output: Contribution to journalReview article

Abstract

Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. We will briefly outline and review the current role of targeted therapy in thymic cancer.

Original languageEnglish (US)
Pages (from-to)1712-1718
Number of pages7
JournalJournal of Oncology Pharmacy Practice
Volume25
Issue number7
DOIs
StatePublished - Oct 1 2019

Fingerprint

Thymoma
Thymus Neoplasms
Neoplasms
Therapeutics
Platinum
Clinical Trials
Guidelines
Drug Therapy
Mutation
Incidence

Keywords

  • Thymic carcinoma
  • mutations
  • targeted therapy
  • thymic epithelial tumors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

The role of targeted therapy in thymic carcinoma. / Krishnan, Mridula; Ganti, Apar K.

In: Journal of Oncology Pharmacy Practice, Vol. 25, No. 7, 01.10.2019, p. 1712-1718.

Research output: Contribution to journalReview article

@article{98ba98fb3a0e4db980a93efe4e6273d7,
title = "The role of targeted therapy in thymic carcinoma",
abstract = "Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. We will briefly outline and review the current role of targeted therapy in thymic cancer.",
keywords = "Thymic carcinoma, mutations, targeted therapy, thymic epithelial tumors",
author = "Mridula Krishnan and Ganti, {Apar K.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1177/1078155219852758",
language = "English (US)",
volume = "25",
pages = "1712--1718",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - The role of targeted therapy in thymic carcinoma

AU - Krishnan, Mridula

AU - Ganti, Apar K.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. We will briefly outline and review the current role of targeted therapy in thymic cancer.

AB - Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. We will briefly outline and review the current role of targeted therapy in thymic cancer.

KW - Thymic carcinoma

KW - mutations

KW - targeted therapy

KW - thymic epithelial tumors

UR - http://www.scopus.com/inward/record.url?scp=85067786172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067786172&partnerID=8YFLogxK

U2 - 10.1177/1078155219852758

DO - 10.1177/1078155219852758

M3 - Review article

C2 - 31159657

AN - SCOPUS:85067786172

VL - 25

SP - 1712

EP - 1718

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 7

ER -